Bipolar Disorder (2018) |
1.54 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Bipolar Disorder or Schizophrenia |
1.28 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
UBE2D3 |
Depressed Affect (Nagel 2018) |
1.20 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC010883.5 |
Neuroticism (Nagel 2018) |
1.54 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC010883.5 |
Schizophrenia (2018) |
1.08 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
UBE2D3 |
Schizophrenia vs Biploar Disorder |
1.51 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Crohns Disease (2017) |
4.13 |
4 |
2 |
4.4 |
-0.42 |
5.8e-01 |
AC010883.5 FNDC4 JAZF1 PPM1N |
Irritable Bowel Disease (IBD) |
3.56 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
AC010883.5 EIF2S2P3 FNDC4 |
Ulcerative Colitis (UC) |
2.50 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC010883.5 UBE2D3 |
Breast Cancer |
3.24 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
CALR TCF7L2 |
Body Mass Index (BMI) (2010) |
2.06 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF7L2 |
Crohns Disease (2012) |
2.61 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC010883.5 FNDC4 |
Fasting Glucose |
9.82 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
LDL Cholesterol |
1.19 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Primary Biliary Cirrhosis |
2.66 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 UBE2D3 |
Schizophrenia (2014) |
1.20 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
UBE2D3 |
Triglycerides |
27.65 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Type 2 Diabetes (T2D) (2012) |
16.54 |
8 |
4 |
8.9 |
0.97 |
8.2e-05 |
AC010883.5 EIF2S2P3 IGF2BP2 JAZF1 TCF7L2 UBE2D3 UBE2E2 WFS1 |
Ulcerative Colitis |
2.37 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC010883.5 |
Blood Eosinophil Count |
2.15 |
3 |
3 |
6.7 |
0.00 |
1.0e+00 |
AC010883.5 EIF2S2P3 JAZF1 |
Blood Platelet Count |
7.43 |
7 |
4 |
8.9 |
-0.19 |
6.8e-01 |
AC010883.5 AP3S2 FNDC4 IGF2BP2 LRRC66 PPM1N UBE2E2 |
Blood Red Count |
2.96 |
5 |
3 |
6.7 |
0.91 |
2.9e-02 |
CALR EIF2S2P3 FNDC4 IGF2BP2 PPM1N |
Blood White Count |
2.86 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 LRRC66 |
Heel T-Score |
1.59 |
4 |
2 |
4.4 |
-0.03 |
9.7e-01 |
AC010883.5 CALR IGF2BP2 JAZF1 |
BMI |
2.18 |
6 |
3 |
6.7 |
-0.46 |
3.6e-01 |
FNDC4 JAZF1 LRRC66 PPM1N TCF7L2 UBE2D3 |
Height |
3.66 |
8 |
5 |
11.1 |
0.03 |
9.5e-01 |
AC010883.5 AP3S2 CALR FNDC4 JAZF1 LRRC66 UBE2D3 UBE2E2 |
Waist Hip Ratio (WHR) |
4.64 |
5 |
4 |
8.9 |
0.89 |
4.2e-02 |
AC010883.5 EIF2S2P3 IGF2BP2 JAZF1 TCF7L2 |
Systolic Blood Pressure |
2.18 |
5 |
2 |
4.4 |
0.68 |
2.1e-01 |
CAMK1D FNDC4 JAZF1 LRRC66 TCF7L2 |
Allergy or Eczema |
2.55 |
4 |
0 |
0.0 |
-0.31 |
6.9e-01 |
AC010883.5 FNDC4 JAZF1 UBE2D3 |
Cardiovascular Disease |
3.56 |
5 |
2 |
4.4 |
0.45 |
4.5e-01 |
CAMK1D FNDC4 IGF2BP2 PPM1N UBE2D3 |
Hypothyroidism (self reported) |
1.42 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC010883.5 IGF2BP2 |
Respiratory disease |
2.30 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
EIF2S2P3 JAZF1 |
Type 2 Diabetes (T2D) (2018) |
36.44 |
13 |
11 |
24.4 |
1.00 |
1.9e-12 |
AC010883.5 AP3S2 CALR CAMK1D EIF2S2P3 FNDC4 IGF2BP2 JAZF1 LRRC66 PPM1N TCF7L2 UBE2E2 WFS1 |
Lung FEV1/FVC ratio |
3.96 |
4 |
3 |
6.7 |
-0.66 |
3.4e-01 |
AC010883.5 CAMK1D IGF2BP2 PPM1N |
Lung FVC |
2.60 |
4 |
2 |
4.4 |
-0.96 |
3.7e-02 |
CAMK1D FNDC4 IGF2BP2 JAZF1 |
Chronotype (morning person) |
2.18 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
PPM1N |
Hair Pigment |
0.67 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
AC010883.5 FNDC4 JAZF1 |
Tanning |
0.80 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
FNDC4 JAZF1 |
Hand grip strength (left) |
1.25 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC010883.5 FNDC4 |
Number of treatments/medications taken |
4.16 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 LRRC66 UBE2D3 |
Sensitivity / hurt feelings |
1.07 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
UBE2D3 |
Relative age of first facial hair |
2.07 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Systolic blood pressure, automated reading |
1.95 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
CAMK1D LRRC66 |
Eye problems/disorders: Diabetes related eye disease |
6.46 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
IGF2BP2 TCF7L2 |
Diabetes (father) |
18.35 |
8 |
4 |
8.9 |
0.99 |
5.2e-07 |
AC010883.5 AP3S2 EIF2S2P3 FNDC4 IGF2BP2 JAZF1 TCF7L2 WFS1 |
Diabetes (mother) |
16.63 |
9 |
3 |
6.7 |
0.99 |
1.2e-07 |
AC010883.5 CALR CAMK1D EIF2S2P3 FNDC4 IGF2BP2 TCF7L2 UBE2E2 WFS1 |
Impedance of leg (right) |
3.73 |
3 |
3 |
6.7 |
0.00 |
1.0e+00 |
AC010883.5 FNDC4 JAZF1 |
Leg fat-free mass (left) |
2.68 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 LRRC66 WFS1 |
Trunk fat percentage |
0.99 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
LRRC66 |
Hand grip strength (right) |
1.14 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Maternal smoking around birth |
1.01 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC010883.5 |
Fed-up feelings |
1.39 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC010883.5 |
Taking other prescription medications |
2.03 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
UBE2D3 |
Heel bone mineral density (BMD) T-score, automated (left) |
1.77 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC010883.5 UBE2D3 |
High blood pressure |
2.39 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
CAMK1D IGF2BP2 UBE2D3 |
Hayfever, allergic rhinitis or eczema |
2.24 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC010883.5 FNDC4 JAZF1 |
Sitting height |
2.03 |
4 |
2 |
4.4 |
0.19 |
8.1e-01 |
FNDC4 JAZF1 UBE2D3 UBE2E2 |
Body mass index (BMI) |
1.97 |
4 |
1 |
2.2 |
-0.59 |
4.1e-01 |
FNDC4 JAZF1 LRRC66 TCF7L2 |
Impedance of leg (left) |
3.96 |
3 |
3 |
6.7 |
0.00 |
1.0e+00 |
AC010883.5 FNDC4 JAZF1 |
Leg predicted mass (left) |
2.70 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 LRRC66 WFS1 |
Trunk fat mass |
1.38 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
JAZF1 LRRC66 TCF7L2 |
Waist circumference |
1.42 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 TCF7L2 |
Forced vital capacity (FVC) |
1.59 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
CALR CAMK1D IGF2BP2 |
Heel bone mineral density (BMD) T-score, automated (right) |
1.39 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC010883.5 |
Heart attack |
2.08 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC010883.5 |
Allergy |
2.38 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC010883.5 JAZF1 UBE2D3 |
Diabetes (self-reported) |
29.14 |
14 |
8 |
17.8 |
0.99 |
1.5e-11 |
AC010883.5 AP3S2 CALR CAMK1D EIF2S2P3 FNDC4 IGF2BP2 JAZF1 LRRC66 PPM1N TCF7L2 UBE2D3 UBE2E2 WFS1 |
Medication: Ramipril |
3.95 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
UBE2D3 |
Medication: Simvastatin |
5.75 |
4 |
1 |
2.2 |
0.45 |
5.5e-01 |
FNDC4 LRRC66 PPM1N TCF7L2 |
Illnesses of siblings |
2.48 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
IGF2BP2 |
Neuroticism score |
1.30 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC010883.5 |
Weight |
2.23 |
4 |
2 |
4.4 |
0.14 |
8.6e-01 |
FNDC4 JAZF1 LRRC66 TCF7L2 |
Impedance of arm (right) |
4.07 |
4 |
3 |
6.7 |
0.10 |
9.0e-01 |
FNDC4 JAZF1 TCF7L2 UBE2D3 |
Arm fat percentage (right) |
1.05 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF7L2 |
Trunk fat-free mass |
3.79 |
4 |
2 |
4.4 |
-0.63 |
3.7e-01 |
FNDC4 JAZF1 LRRC66 WFS1 |
Hip circumference |
2.20 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
FNDC4 LRRC66 TCF7L2 |
Alcohol intake versus 10 years previously |
3.62 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Father's age at death |
1.61 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
LRRC66 |
Worrier / anxious feelings |
1.67 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF7L2 |
Hair/balding pattern: Pattern 3 |
1.40 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
UBE2E2 |
Number of live births |
1.32 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
UBE2D3 |
Forced expiratory volume in 1-second (FEV1) |
2.65 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
CALR CAMK1D IGF2BP2 |
Pulse rate |
3.84 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Mouth/teeth dental problems: Dentures |
1.47 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Asthma |
2.28 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
EIF2S2P3 JAZF1 |
Medication: Cholesterol lowering |
7.60 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 IGF2BP2 TCF7L2 |
Illnesses of mother |
2.32 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
IGF2BP2 |
Forced expiratory volume in 1-second (FEV1), Best measure |
2.52 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
CAMK1D IGF2BP2 |
Impedance of arm (left) |
4.67 |
6 |
3 |
6.7 |
-0.11 |
8.4e-01 |
AC010883.5 CALR FNDC4 JAZF1 TCF7L2 UBE2D3 |
Arm fat mass (right) |
1.50 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 LRRC66 TCF7L2 |
Trunk predicted mass |
3.80 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
FNDC4 JAZF1 LRRC66 |
Standing height |
3.49 |
5 |
2 |
4.4 |
0.61 |
2.7e-01 |
CALR FNDC4 JAZF1 LRRC66 UBE2E2 |
Hair/balding pattern: Pattern 4 |
1.37 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC010883.5 |
Birth weight of first child |
1.67 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
IGF2BP2 |
Peak expiratory flow (PEF) |
3.37 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
AC010883.5 CAMK1D IGF2BP2 |
Headache pain in last month |
2.02 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
UBE2D3 |
Medication for cholesterol, blood pressure or diabetes |
5.86 |
5 |
0 |
0.0 |
-0.62 |
2.6e-01 |
CAMK1D FNDC4 IGF2BP2 PPM1N UBE2D3 |
Gout (self-reported) |
6.84 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Hypothyroidism/myxoedema (self-reported) |
1.47 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
IGF2BP2 |
Birth weight |
2.97 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
EIF2S2P3 |
High blood pressure (siblings) |
2.10 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Forced vital capacity (FVC), Best measure |
1.48 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CAMK1D JAZF1 |
Body fat percentage |
1.11 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF7L2 |
Leg fat percentage (right) |
1.41 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
TCF7L2 |
Arm fat-free mass (right) |
3.64 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 JAZF1 LRRC66 |
Comparative body size at age 10 |
1.44 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Age at first live birth |
1.39 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
EIF2S2P3 |
Medication for pain relief, constipation, heartburn |
2.70 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
UBE2D3 |
Medication: Blood pressure |
3.45 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
CAMK1D PPM1N UBE2D3 |
Migraine (self-reported) |
2.05 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
UBE2D3 |
Medication: Allopurinol |
6.15 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Reproduciblity of spirometry measurement using ERS/ATS criteria |
1.91 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF7L2 |
Whole body fat mass |
1.48 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 LRRC66 TCF7L2 |
Leg fat mass (right) |
1.72 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 LRRC66 TCF7L2 |
Arm predicted mass (right) |
3.62 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 JAZF1 LRRC66 |
Pulse rate, automated reading |
4.93 |
4 |
2 |
4.4 |
0.32 |
6.8e-01 |
AC010883.5 FNDC4 JAZF1 WFS1 |
Alcohol intake frequency. |
7.04 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 LRRC66 |
Comparative height size at age 10 |
3.96 |
6 |
3 |
6.7 |
0.35 |
4.9e-01 |
AC010883.5 EIF2S2P3 FNDC4 JAZF1 LRRC66 UBE2E2 |
Overall health rating |
1.95 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
UBE2D3 |
Age at last live birth |
1.34 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
EIF2S2P3 |
Medication: Aspirin |
4.82 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
IGF2BP2 LRRC66 |
Hypertension (Self-reported) |
2.43 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
CAMK1D IGF2BP2 UBE2D3 |
Illnesses of father: Heart disease |
1.80 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Illnesses of siblings: Diabetes |
10.76 |
6 |
3 |
6.7 |
0.99 |
2.9e-04 |
AC010883.5 CAMK1D EIF2S2P3 IGF2BP2 TCF7L2 WFS1 |
Smoking status: Previous |
1.25 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CALR |
Forced expiratory volume in 1-second (FEV1), predicted |
3.03 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
JAZF1 |
Whole body fat-free mass |
3.45 |
4 |
1 |
2.2 |
-0.69 |
3.1e-01 |
FNDC4 JAZF1 LRRC66 WFS1 |
Leg fat-free mass (right) |
2.64 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 LRRC66 WFS1 |
Arm fat percentage (left) |
0.98 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF7L2 |
Mood swings |
1.26 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC010883.5 |
Long-standing illness, disability or infirmity |
2.84 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
IGF2BP2 |
Diabetes diagnosed by doctor |
32.81 |
14 |
10 |
22.2 |
0.99 |
8.8e-13 |
AC010883.5 AP3S2 CALR CAMK1D EIF2S2P3 FNDC4 IGF2BP2 JAZF1 LRRC66 PPM1N TCF7L2 UBE2D3 UBE2E2 WFS1 |
Qualifications: nursing, teaching |
1.03 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF7L2 |
Medication for cholesterol |
3.42 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 UBE2D3 |
Breast cancer (self-reported) |
1.52 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF7L2 |
Asthma (self-reported) |
2.14 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
EIF2S2P3 JAZF1 |
Osteoporosis (self-reported) |
1.15 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Medication: Aspirin |
5.06 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
IGF2BP2 LRRC66 |
Medication: Gliclazide |
14.50 |
6 |
2 |
4.4 |
1.00 |
2.7e-06 |
FNDC4 IGF2BP2 JAZF1 TCF7L2 UBE2E2 WFS1 |
Illnesses of father: None of the above (group 1) |
2.75 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CAMK1D |
Forced expiratory volume in 1-second (FEV1), predicted percentage |
2.73 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
CAMK1D IGF2BP2 JAZF1 |
Whole body water mass |
3.47 |
4 |
1 |
2.2 |
-0.69 |
3.1e-01 |
FNDC4 JAZF1 LRRC66 WFS1 |
Leg predicted mass (right) |
2.63 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 LRRC66 WFS1 |
Arm fat mass (left) |
1.39 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 LRRC66 TCF7L2 |
Number of self-reported non-cancer illnesses |
4.27 |
4 |
1 |
2.2 |
0.49 |
5.1e-01 |
FNDC4 IGF2BP2 JAZF1 UBE2D3 |
Guilty feelings |
1.26 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AP3S2 |
Medication: Blood pressure |
2.00 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
UBE2D3 |
High cholesterol (Self-reported) |
8.16 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Medication: Paracetamol |
2.43 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
UBE2D3 |
Medication: Atorvastatin |
6.77 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 TCF7L2 |
Basal metabolic rate |
3.14 |
5 |
1 |
2.2 |
0.26 |
6.8e-01 |
FNDC4 JAZF1 LRRC66 TCF7L2 WFS1 |
Leg fat percentage (left) |
1.43 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
TCF7L2 |
Arm fat-free mass (left) |
3.53 |
5 |
1 |
2.2 |
0.25 |
6.9e-01 |
FNDC4 JAZF1 LRRC66 TCF7L2 WFS1 |
Irritability |
1.74 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC010883.5 |
Diastolic blood pressure, automated reading |
1.17 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF7L2 UBE2D3 |
Vascular/heart problems diagnosed by doctor |
2.82 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
IGF2BP2 PPM1N UBE2D3 |
Cholesterol lowering medication |
5.58 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 LRRC66 TCF7L2 |
Heart attack/myocardial infarction (self-reported) |
1.95 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC010883.5 |
Impedance of whole body |
4.61 |
6 |
4 |
8.9 |
-0.11 |
8.3e-01 |
AC010883.5 FNDC4 JAZF1 TCF7L2 UBE2D3 WFS1 |
Leg fat mass (left) |
1.79 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 LRRC66 TCF7L2 |
Arm predicted mass (left) |
3.45 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 JAZF1 LRRC66 |